Source:http://linkedlifedata.com/resource/pubmed/id/19912215
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2010-1-20
|
| pubmed:abstractText |
From 2002 to 2007, 49 myeloma patients who relapsed following autologous SCT were included in a prospective multicenter trial to determine the efficacy of a reduced melphalan/fludarabine regimen followed by allogeneic SCT from unrelated donors. All patients showed leucocyte and platelet engraftment after a median of 15 and 19 d, respectively. Grade II-IV acute graft-versus-host disease (GvHD) occurred in 25% of patients and 35% had chronic GvHD. Overall response rate at day 100 was 95% including 46% complete remission (CR). Cumulative incidence of non-relapse mortality at 1 year was 25% [95% confidence interval (CI): 13-37%] and was significantly lower for human leucocyte antigen (HLA)-matched compared to -mismatched SCT (10% vs. 53%, P = 0.001). The cumulative incidence of relapse at 3 years was 55% (95% CI: 40-70%). After a median follow up of 43 months, the estimated 5-year progression-free and overall survival rates were 20% and 26% respectively and were significantly better for matched in CR at day 100 (41% vs. 7%, P = 0.04 and 56% vs. 16%, P = 0.02). We conclude that optimal donor selection is mandatory for a low non-relapse mortality and high relapse incidence, which remains a major concern, should be improved by including post-transplant strategies to upgrade remission status.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
1365-2141
|
| pubmed:author |
pubmed-author:BornhäuserMartinM,
pubmed-author:BrandRonaldR,
pubmed-author:GahrtonGöstaG,
pubmed-author:HeinzelmannMarionM,
pubmed-author:KrögerNicolausN,
pubmed-author:MorrisCurlyC,
pubmed-author:NaglerArnonA,
pubmed-author:NiederwieserDietgerD,
pubmed-author:SchillingGeorgiaG,
pubmed-author:SchwerdtfegerRainerR,
pubmed-author:ShimoniAvichaiA,
pubmed-author:ZanderAxel RAR,
pubmed-author:de WitteTheoT
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
148
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
323-31
|
| pubmed:meshHeading |
pubmed-meshheading:19912215-Adolescent,
pubmed-meshheading:19912215-Adult,
pubmed-meshheading:19912215-Antineoplastic Agents,
pubmed-meshheading:19912215-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19912215-Combined Modality Therapy,
pubmed-meshheading:19912215-Disease-Free Survival,
pubmed-meshheading:19912215-Female,
pubmed-meshheading:19912215-Graft vs Host Disease,
pubmed-meshheading:19912215-Humans,
pubmed-meshheading:19912215-Male,
pubmed-meshheading:19912215-Melphalan,
pubmed-meshheading:19912215-Middle Aged,
pubmed-meshheading:19912215-Multiple Myeloma,
pubmed-meshheading:19912215-Prospective Studies,
pubmed-meshheading:19912215-Recurrence,
pubmed-meshheading:19912215-Stem Cell Transplantation,
pubmed-meshheading:19912215-Survival Analysis,
pubmed-meshheading:19912215-Transplantation, Autologous,
pubmed-meshheading:19912215-Transplantation, Homologous,
pubmed-meshheading:19912215-Vidarabine,
pubmed-meshheading:19912215-Young Adult
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation.
|
| pubmed:affiliation |
University Hospital Hamburg-Eppendorf, Germany. nkroeger@uke.uni-hamburg.de
|
| pubmed:publicationType |
Journal Article,
Multicenter Study
|